Epidermal Growth Factor Receptor (EGFR) cell expression during adjuvant treatment after transurethral resection for Non-Muscle Invasive Bladder Cancer: a new potential tool to identify patients at higher risk of disease progression

The prognosis of non-muscle invasive bladder cancer (NMIBC) is not homogeneous. Although the management of NMIBC has significantly improved during the past few years, it remains difficult to predict the oncologic outcomes of such tumors, especially if high-grade NMIBC is present. Aim of the present paper was to assess the feasibility and prognostic role of EGFR evaluation in bladder washing of patients treated with TURBT and intravesical adjuvant therapy. In our experience, EGFR overexpression resulted an independent prognostic factor of disease recurrence and progression.